GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Pediatric Blood & Cancer, Wiley, Vol. 66, No. 10 ( 2019-10)
    Abstract: Overall survival rates for pediatric patients with high‐risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 1296-1296
    Abstract: Introduction: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. In the United States, about 350 children are diagnosed with RMS per year. The two major histologic subtypes of RMS are embryonal (ERMS; approximately 70% of cases) and alveolar (ARMS; approximately 30% of cases). A small percentage of RMS cases are associated with germline mutations in TP53, HRAS, and NF1. However, it has been difficult to show if inherited susceptibility may play a role in sporadic cases due to the rarity of these tumors and the potential etiologic heterogeneity between subtypes. Objective: In order to better characterize genetic susceptibility to childhood RMS, we evaluated the role of family history of cancer using data from the largest case-control study of RMS to date. Methods: Cases (n=322) were enrolled from the third trial run by the Intergroup Rhabdomyosarcoma Study Group. Population-based controls (n=322) were pair matched to cases on race, sex, and age. Conditional logistic regression was used to evaluate cancer history among first- and second-degree relatives and the association with childhood RMS by generating adjusted odds ratios (aOR) and 95% confidence intervals (CI). Stratified analyses were conducted to independently evaluate the association of family cancer history and childhood RMS for children who had relatives diagnosed with a cancer before the age of 40 years and those with relatives diagnosed when older than 40 years. The association of family cancer history and childhood RMS was also assessed separately for children diagnosed with ERMS and those diagnosed with ARMS. Results: While there were no statistically significant associations, three patterns appeared to emerge: 1) having any first degree relative with a history of cancer was more common in RMS cases than controls (aOR=1.46, 95% CI: 0.72-2.97); 2) having a first degree relative who was younger at diagnosis ( & lt;40 years of age) appeared to convey a greater risk of RMS (aOR=1.55, 95% CI: 0.96-2.51); and 3) having a first degree relative with cancer was more common for those with ERMS compared to ARMS (aOR=1.58, 95% CI: 0.61-4.10 vs. aOR=1.01, 95% CI: 0.29-3.50, respectively). Conclusions: In the largest analysis of its kind to date, we found that family history of cancer appeared to increase the risk of childhood RMS. While the associations were not statistically significant, this is likely due to the low prevalence of family cancer history in this population (i.e., 6.6% overall). Ultimately, these findings tentatively support the role of inherited genetic susceptibility in the development of childhood RMS. Citation Format: Philip J. Lupo, Heather E. Danysh, Sharon E. Plon, David Malkin, Simone Hettmer, Douglas S. Hawkins, Stephen X. Skapek, Logan G. Spector, Karin Papworth, Beatrice Melin, Erik B. Erhardt, Seymour Grufferman. Family history of cancer and rhabdomyosarcoma in children: a report from the Children's Oncology Group. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1296. doi:10.1158/1538-7445.AM2014-1296
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Medicine, Wiley, Vol. 4, No. 5 ( 2015-05), p. 781-790
    Abstract: Relatively little is known about the epidemiology and factors underlying susceptibility to childhood rhabdomyosarcoma ( RMS ). To better characterize genetic susceptibility to childhood RMS , we evaluated the role of family history of cancer using data from the largest case–control study of RMS and the Utah Population Database ( UPDB ). RMS cases ( n  = 322) were obtained from the Children's Oncology Group ( COG ). Population‐based controls ( n  = 322) were pair‐matched to cases on race, sex, and age. Conditional logistic regression was used to evaluate the association between family history of cancer and childhood RMS . The results were validated using the UPDB , from which 130 RMS cases were identified and matched to controls ( n  = 1300) on sex and year of birth. The results were combined to generate summary odds ratios ( OR s ) and 95% confidence intervals ( CI ). Having a first‐degree relative with a cancer history was more common in RMS cases than controls ( OR s  = 1.39, 95% CI : 0.97–1.98). Notably, this association was stronger among those with embryonal RMS ( OR s  = 2.44, 95% CI : 1.54–3.86). Moreover, having a first‐degree relative who was younger at diagnosis of cancer ( 〈 30 years) was associated with a greater risk of RMS ( OR s  = 2.37, 95% CI : 1.34–4.18). In the largest analysis of its kind, we found that most children diagnosed with RMS did not have a family history of cancer. However, our results indicate an increased risk of RMS (particularly embryonal RMS ) in children who have a first‐degree relative with cancer, and among those whose relatives were diagnosed with cancer at 〈 30 years of age.
    Type of Medium: Online Resource
    ISSN: 2045-7634 , 2045-7634
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 2659751-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 13_Supplement ( 2018-07-01), p. 2966-2966
    Abstract: Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and has one of the poorest survival rates among all pediatric cancers. The two major histologic subtypes of RMS are embryonal (eRMS) and alveolar (aRMS), which display differences in terms of age-incidence patterns and somatic mutations. Approximately 10% of RMS cases are associated with germline mutations in known cancer predisposition genes (e.g., TP53, NF1), but very little is known about the genetic susceptibility to the ~90% of RMS cases that are sporadic. We conducted the first multi-institutional genome-wide association study (GWAS) of RMS in 727 cases and 3,384 controls. Methods: Phase 1 of the GWAS included 421 RMS cases from Children's Oncology Group clinical trials, Texas Children's Hospital, and the Universidad de Navarra. Controls (n=2,763) were cancer-free individuals included in previous studies at the National Cancer Institute (NCI). Phase 2 included 306 cases from the Childhood Cancer Survivor Study and 621 independent controls from NCI. Genotypes were generated using the Illumina OmniExpress or the HumanOmni5Exome array and imputed based on the 1000 Genomes Project. Analyses were restricted to those of European (EUR) ancestry, and controls were matched to the cases based on principal components and genotype platform. Assuming an additive genetic model in SNPTEST, we used multivariable logistic regression models to estimate the odds ratio (OR), 95% confidence interval (CI), and P value for each variant on RMS overall and by two RMS subtypes: eRMS and aRMS. Results: After quality control filtering and assessment of population substructure, there were 555 combined EUR RMS cases and 1,561 controls, which included: 1) 278 cases and 1,112 controls in phase 1; and 2) 277 cases and 449 controls in phase 2. In the combined set, we identified a new locus at chromosome 11p15.2 that was strongly associated with an increased risk of aRMS and significant at the genome-wide level (OR=2.3, P=2.2x10-8). Results were consistent across studies: phase 1 OR=2.3, 95% CI 1.7-3.2; and phase 2 OR=2.3, 95% CI 1.2-4.5. The top variant, rs12785926, mapped to an intron in the PSMA1 (proteasome subunit alpha 1) gene. Based on data from GTEx, rs12785926 is significantly associated with RRAS2 expression across multiple tissues. RRAS2 is involved in cell proliferation and is somatically mutated in several tumors. When evaluating eRMS and RMS overall in the combined set, there were no variants significant at the genome-wide level. Conclusion: In the first GWAS of pediatric RMS, we identified a susceptibility locus associated with the more aggressive aRMS subtype that has a poorer prognosis. Additional replication analyses are underway using DNA obtained from archived newborn blood spots linked to population-based cancer registries, as well as other institutional cohorts. Further investigation will advance understanding of RMS etiology and biology. Citation Format: Philip J. Lupo, Libby Morimoto, Eric Karlins, Xiaorong Shao, Lindsay M. Morton, Michael E. Scheurer, Smita Bhatia, Leslie L. Robison, Gregory T. Armstrong, Simone Hettmer, Javed Khan, Stephen J. Chanock, Neal D. Freedman, Kathleen Wyatt, Belynda D. Hicks, Meredith Yeager, Casey L. Dagnall, Shengchao A. Li, Stephen X. Skapek, Douglas S. Hawkins, Catherine Metayer, Lisa Mirabello. A genome-wide scan identifies a new locus associated with pediatric rhabdomyosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2966.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: European Journal of Cancer, Elsevier BV, Vol. 172 ( 2022-09), p. 367-386
    Type of Medium: Online Resource
    ISSN: 0959-8049
    RVK:
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2022
    detail.hit.zdb_id: 1120460-6
    detail.hit.zdb_id: 1468190-0
    detail.hit.zdb_id: 82061-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer, Wiley, Vol. 122, No. 22 ( 2016-11-15), p. 3492-3500
    Abstract: The current study presents the hypothesis that cancer‐predisposing germline mutations are less common among patients with fusion‐positive sarcomas compared to those with fusion‐negative sarcomas. In support of this hypothesis, the risk of a second cancer among survivors of sarcomas diagnosed between 1992 and 2012 was found to be nearly 2‐fold greater among survivors of fusion‐positive sarcomas (standardized incidence ratio, 1.86; 95% confidence interval, 1.48‐2.30) and nearly 3‐fold greater among survivors of fusion‐negative sarcomas (standardized incidence ratio, 2.89; 95% confidence interval, 2.30‐3.59) compared with the reference population.
    Type of Medium: Online Resource
    ISSN: 0008-543X , 1097-0142
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 1479932-7
    detail.hit.zdb_id: 2599218-1
    detail.hit.zdb_id: 2594979-2
    detail.hit.zdb_id: 1429-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...